2018
Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells
Sullivan-Reed K, Bolton-Gillespie E, Dasgupta Y, Langer S, Siciliano M, Nieborowska-Skorska M, Hanamshet K, Belyaeva EA, Bernhardy AJ, Lee J, Moore M, Zhao H, Valent P, Matlawska-Wasowska K, Müschen M, Bhatia S, Bhatia R, Johnson N, Wasik MA, Mazin AV, Skorski T. Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. Cell Reports 2018, 23: 3127-3136. PMID: 29898385, PMCID: PMC6082171, DOI: 10.1016/j.celrep.2018.05.034.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBRCA1 ProteinBRCA2 ProteinDNA RepairFemaleFusion Proteins, bcr-ablHomologous RecombinationHumansImatinib MesylateKaplan-Meier EstimateLeukemia, Myeloid, AcuteMaleMiceMice, Inbred NODMice, KnockoutPhthalazinesPiperazinesPoly (ADP-Ribose) Polymerase-1Rad52 DNA Repair and Recombination ProteinSynthetic Lethal MutationsTumor Suppressor p53-Binding Protein 1ConceptsTumor cellsBRCA-deficient tumor cellsSimultaneous targetingBRCA-deficient tumorsClinical trialsProlonged latencyImmunodeficient miceTherapeutic outcomesBRCA1-deficient tumorsPARP inhibitorsBRCA-deficient cellsMinimal toxicitySynergistic activitySynthetic lethal effectTumorsNormal cellsPARPiSynthetic lethalityInhibitorsLethal effectsCellsDominant negative mutantSynergistic accumulationMalignancyTargeting
2015
Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia
Chen Z, Shojaee S, Buchner M, Geng H, Lee JW, Klemm L, Titz B, Graeber TG, Park E, Tan YX, Satterthwaite A, Paietta E, Hunger SP, Willman CL, Melnick A, Loh ML, Jung JU, Coligan JE, Bolland S, Mak TW, Limnander A, Jumaa H, Reth M, Weiss A, Lowell CA, Müschen M. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature 2015, 521: 357-361. PMID: 25799995, PMCID: PMC4441554, DOI: 10.1038/nature14231.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid MotifsAnimalsAntigens, CDB-LymphocytesCell DeathCell Line, TumorCell Transformation, NeoplasticDisease Models, AnimalDrug Resistance, NeoplasmEnzyme ActivationFemaleFusion Proteins, bcr-ablGene DeletionHumansInositol Polyphosphate 5-PhosphatasesIntracellular Signaling Peptides and ProteinsMiceMice, Inbred NODMice, SCIDPhosphatidylinositol-3,4,5-Trisphosphate 5-PhosphatasesPhosphoric Monoester HydrolasesPlatelet Endothelial Cell Adhesion Molecule-1Precursor Cell Lymphoblastic Leukemia-LymphomaPrecursor Cells, B-LymphoidProtein Tyrosine Phosphatase, Non-Receptor Type 6Protein-Tyrosine KinasesReceptors, Antigen, B-CellReceptors, ImmunologicSignal TransductionSyk KinaseTyrosineXenograft Model Antitumor Assays
2013
Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile
Cramer-Morales K, Nieborowska-Skorska M, Scheibner K, Padget M, Irvine DA, Sliwinski T, Haas K, Lee J, Geng H, Roy D, Slupianek A, Rassool FV, Wasik MA, Childers W, Copland M, Müschen M, Civin CI, Skorski T. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood 2013, 122: 1293-1304. PMID: 23836560, PMCID: PMC3744994, DOI: 10.1182/blood-2013-05-501072.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisAptamers, PeptideBiomarkers, TumorBlotting, WesternBRCA1 ProteinBRCA2 ProteinCase-Control StudiesCell DifferentiationCell ProliferationDNA DamageDNA RepairEpigenomicsFusion Proteins, bcr-ablGene Expression ProfilingHumansLeukemia, Lymphocytic, Chronic, B-CellMiceMice, SCIDModels, MolecularMutationNeoplasm Recurrence, LocalNeoplastic Stem CellsOligonucleotide Array Sequence AnalysisPeptide FragmentsRad51 RecombinaseRad52 DNA Repair and Recombination ProteinReal-Time Polymerase Chain ReactionRecombination, GeneticReverse Transcriptase Polymerase Chain ReactionRNA, MessengerTumor Cells, CulturedXenograft Model Antitumor Assays